Somatic Symptom and Functional Neurological Disorders: Neurobiological Mechanisms, CBT, and Multidisciplinary Treatment Approaches

Somatic symptom disorder (SSD) and functional neurological disorder (FND) represent a cluster of conditions at the intersection of neurology, psychiatry, and psychology — conditions where subjective bodily distress and neurological dysfunction occur in the absence of, or in excess of, identifiable structural pathology. These disorders are neither "imaginary" nor "purely psychological"; they reflect genuine disruptions in the brain's integration of sensory, motor, emotional, and cognitive processing. Understanding them demands a move beyond the outdated mind-body dualism that has historically marginalized these patients.

The DSM-5-TR classifies somatic symptom and related disorders as a discrete diagnostic category that includes somatic symptom disorder, illness anxiety disorder, conversion disorder (functional neurological symptom disorder), psychological factors affecting other medical conditions, and factitious disorder. The ICD-11 introduced the parallel category of bodily distress disorder, shifting emphasis from medically unexplained symptoms toward the positive identification of excessive cognitive, emotional, and behavioral responses to somatic experiences. This reconceptualization was a deliberate effort to reduce stigma and improve diagnostic reliability.

The clinical significance of these conditions is enormous. They account for an estimated 15–30% of primary care consultations and generate substantial healthcare costs through repeated investigations, specialist referrals, and unnecessary interventions. Patients with SSD and FND experience marked functional impairment, high rates of psychiatric comorbidity, and significant reduction in quality of life — often comparable to or exceeding that seen in major neurological disease. Despite this burden, these conditions remain underdiagnosed, undertreated, and frequently misunderstood by clinicians across specialties.

Precise epidemiological estimates for somatic symptom and functional neurological disorders vary depending on the diagnostic criteria used, the clinical setting, and the population studied. The shift from DSM-IV somatoform disorders to DSM-5 somatic symptom disorder broadened the diagnostic net, capturing patients previously excluded because their symptoms had identifiable medical explanations.

Somatic Symptom Disorder

Population-based estimates suggest that SSD, as defined by DSM-5 criteria, affects approximately 5–7% of the general adult population. In primary care settings, prevalence estimates are considerably higher, ranging from 15–25% depending on severity thresholds. A landmark epidemiological analysis by Creed and Barsky (2004) estimated that medically unexplained symptoms — the broader phenotype overlapping with SSD — accounted for approximately 30–50% of outpatient medical encounters. Women are disproportionately affected, with female-to-male ratios of approximately 2:1 to 10:1 depending on the specific symptom cluster. Onset typically occurs in young adulthood (ages 20–30), though presentation to specialists often occurs years later after extensive medical workup.

Functional Neurological Disorder

FND (conversion disorder) has an estimated incidence of 4–12 per 100,000 per year, making it one of the most common diagnoses in outpatient neurology clinics — accounting for approximately 6% of neurology outpatient referrals and up to 16% of new neurology consultations in some studies. The seminal Scottish Neurological Symptoms Study (Stone et al., 2009) found that functional symptoms were the second most common reason for neurological outpatient attendance, trailing only headache. Functional seizures (psychogenic nonepileptic seizures, PNES) have a prevalence of approximately 2–33 per 100,000, and functional motor symptoms — including weakness, tremor, and dystonia — are frequently encountered. FND also shows a female predominance (approximately 2–3:1), though this ratio is less skewed for certain symptom types such as functional tremor.

Economic and Functional Impact

Healthcare utilization among patients with somatization-spectrum disorders is approximately 6–14 times higher than population averages. A U.S. estimate placed annual excess healthcare costs attributable to somatization at over $256 billion. Beyond financial metrics, patients with SSD and FND exhibit functional disability scores comparable to those with multiple sclerosis, Parkinson's disease, and epilepsy, with significant impairment in employment, social participation, and activities of daily living.

Contemporary neuroscience has moved decisively away from the psychoanalytic framework that once dominated the conceptualization of conversion and somatic symptom disorders. Advances in structural and functional neuroimaging, electrophysiology, and computational psychiatry have revealed that these conditions involve measurable alterations in brain structure, connectivity, and function — particularly in circuits governing interoception, emotional regulation, motor control, and self-agency.

Aberrant Interoceptive Processing

The anterior insula serves as the primary cortical hub for interoception — the brain's representation of internal bodily states. In SSD, functional MRI studies consistently demonstrate heightened insular activation in response to somatic stimuli, reflecting amplified interoceptive signaling. This is accompanied by increased connectivity between the insula and the dorsal anterior cingulate cortex (dACC), a region involved in salience detection and the affective dimension of bodily sensation. The result is a neural architecture that preferentially amplifies, attends to, and catastrophizes about normal or mildly abnormal somatic signals. Bayesian computational models have conceptualized this as an imbalance in predictive processing: excessively strong somatic "priors" (top-down predictions of illness or dysfunction) override weak bottom-up sensory evidence, generating persistent symptom experience in the absence of peripheral pathology.

Functional Neurological Disorder: Disrupted Agency and Motor Planning

In FND, the neurobiological signature centers on disrupted communication between limbic-emotional circuits and motor planning/execution networks. Key findings include:

• Temporoparietal junction (TPJ): The TPJ, critical for the sense of agency and body ownership, shows altered activation during functional motor symptoms. Patients with functional weakness demonstrate reduced TPJ activation during movement preparation, suggesting a disruption in the neural signal that normally tags voluntary actions as self-generated.
• Amygdala-motor cortex coupling: Voon and colleagues (2010, 2011) demonstrated abnormally increased functional connectivity between the amygdala and the supplementary motor area (SMA) in patients with functional motor symptoms. This finding suggests that emotional arousal directly modulates motor planning circuits, providing a plausible mechanism by which psychological states produce genuine motor dysfunction.
• Prefrontal-motor disconnection: During attempted movement, patients with functional limb weakness show decreased activation of the dorsolateral prefrontal cortex (DLPFC) and reduced coupling between prefrontal regions and the primary motor cortex, consistent with impaired volitional motor initiation despite intact lower motor pathways.

Neurotransmitter Systems

Evidence regarding specific neurotransmitter involvement is less definitive but emerging. The serotonergic system is implicated through the high comorbidity of SSD/FND with depression and anxiety — conditions characterized by serotonin dysregulation — and the partial therapeutic efficacy of SSRIs. The noradrenergic system, governing arousal and threat detection via the locus coeruleus, likely contributes to the hypervigilance and somatic hyperarousal seen in both conditions. Dopaminergic circuits — particularly mesolimbic and mesocortical pathways — may play a role in aberrant salience attribution to innocuous bodily sensations, analogous to the salience dysregulation model proposed for psychosis. Some PET imaging data suggest reduced striatal dopamine receptor binding in patients with functional motor symptoms, though replication is needed. The hypothalamic-pituitary-adrenal (HPA) axis shows dysregulation in subsets of patients, with altered cortisol rhythms linked to early-life adversity — a major risk factor for both SSD and FND.

Genetic and Epigenetic Factors

Twin studies suggest moderate heritability for somatization traits (approximately 30–50%), with shared genetic variance between somatization and neuroticism, anxiety, and depression. Specific candidate genes have not been firmly established, though polymorphisms in the serotonin transporter gene (5-HTTLPR) and genes regulating the HPA axis (FKBP5) have been investigated. Epigenetic modifications — particularly DNA methylation changes associated with childhood trauma — represent a promising research frontier, as they may mediate the well-established link between early adversity and later somatic symptom presentation.

The diagnostic approach to SSD and FND underwent substantial revision with the DSM-5, and further refinement in the DSM-5-TR and ICD-11. Clinicians must understand both the positive diagnostic criteria and the differential diagnosis pitfalls that plague this domain.

DSM-5-TR: Somatic Symptom Disorder (300.82)

Diagnosis requires: (A) one or more somatic symptoms that are distressing or result in significant disruption of daily life; (B) excessive thoughts, feelings, or behaviors related to the somatic symptoms, manifested by at least one of: disproportionate and persistent thoughts about symptom seriousness, persistently high anxiety about health or symptoms, or excessive time and energy devoted to symptoms; (C) symptom persistence (typically >6 months). Crucially, SSD does not require that symptoms be medically unexplained. A patient with confirmed coronary artery disease may still meet criteria if their cognitive, emotional, and behavioral response to the condition is disproportionate. This was a deliberate design choice to avoid the unreliable clinical judgment of whether a symptom is "adequately explained" by pathology.

DSM-5-TR: Conversion Disorder / Functional Neurological Symptom Disorder (300.11)

Diagnosis requires: (A) one or more symptoms of altered voluntary motor or sensory function; (B) clinical findings providing evidence of incompatibility between the symptom and recognized neurological or medical conditions; (C) the symptom is not better explained by another medical or mental disorder; (D) the symptom causes clinically significant distress or impairment. The DSM-5 removed the previous requirement to identify a psychological stressor — a welcome change, since many FND patients present without a clearly identifiable precipitant. Positive clinical signs are now emphasized for diagnosis: Hoover's sign for functional leg weakness, entrainment and distractibility for functional tremor, and specific semiology for psychogenic nonepileptic seizures (e.g., asynchronous limb movements, eye closure during the event, preserved pupillary light reflex).

ICD-11: Bodily Distress Disorder (6C20)

The ICD-11 introduced bodily distress disorder as a unified construct replacing the multiple DSM-IV somatoform subtypes. It emphasizes excessive attention to bodily symptoms and associated distress, with mild, moderate, and severe severity specifiers. The ICD-11 also reclassified FND under "Disorders of Bodily Distress or Bodily Experience" — a move reflecting the conceptual bridge between functional neurological symptoms and broader somatic symptom presentations.

Differential Diagnosis Pitfalls

Misdiagnosis rates in this domain are significant — and the errors run in both directions:

• Diagnostic error rate for FND: Early studies suggested that up to 30% of patients diagnosed with "hysteria" were later found to have neurological disease. However, Stone et al. (2005) conducted a systematic review of studies from 1965 onward and found that the misdiagnosis rate had fallen to approximately 5%, comparable to other neurological diagnoses. Modern neuroimaging and clinical sign-based diagnosis have substantially improved accuracy.
• Failure to diagnose FND/SSD: Perhaps the more common contemporary error is the failure to make a positive diagnosis, resulting in years of unnecessary investigation. The median diagnostic delay for FND is estimated at 5–7 years.
• Key differentials for FND: Multiple sclerosis (especially early-stage with fluctuating symptoms), myasthenia gravis, epilepsy (vs. PNES — approximately 10–20% of patients referred to epilepsy monitoring units have PNES, and approximately 10% of those also have comorbid epilepsy), systemic lupus erythematosus with CNS involvement, and early neurodegenerative disease.
• Key differentials for SSD: Undiagnosed autoimmune disorders, endocrine conditions (especially hypothyroidism and adrenal insufficiency), occult malignancy, and the genuinely excessive health anxiety of illness anxiety disorder (distinguished from SSD by the relative absence of distressing somatic symptoms themselves).
• Comorbidity complicates diagnosis: A substantial minority of patients with confirmed neurological disease (e.g., epilepsy, MS) also have co-occurring functional symptoms. The presence of organic pathology does not exclude FND, and the presence of functional symptoms does not exclude organic pathology.

Both SSD and FND are characterized by high rates of psychiatric comorbidity, which complicate clinical management and influence treatment outcomes. Understanding these comorbidity patterns is essential for comprehensive treatment planning.

Prevalence of Psychiatric Comorbidities

• Major depressive disorder: Co-occurs in approximately 50–70% of patients with SSD and 40–60% of patients with FND. Depression is both a risk factor for symptom onset and a consequence of chronic disability.
• Anxiety disorders: Generalized anxiety, panic disorder, and health anxiety are present in 40–60% of SSD patients. In FND, anxiety disorders are present in approximately 30–50% of cases.
• PTSD and trauma history: A history of psychological trauma (including childhood abuse, neglect, and adverse childhood experiences) is reported in 30–70% of FND patients, depending on the study and trauma assessment method. PTSD specifically co-occurs in approximately 25–35%. The ACE (Adverse Childhood Experiences) score is significantly elevated relative to population norms.
• Dissociative disorders: Dissociative symptoms — particularly depersonalization and derealization — are present in up to 40–50% of FND patients. Conceptually, FND has been described as a form of "motor dissociation," and this overlap has empirical support.
• Personality disorder traits: Cluster B and Cluster C personality features (particularly borderline and avoidant traits) are overrepresented, though earlier literature likely overestimated the association due to selection bias and stigmatization. Structured assessments suggest personality disorder prevalence of approximately 25–40% in FND cohorts.
• Chronic pain syndromes: Fibromyalgia, chronic widespread pain, irritable bowel syndrome, and chronic fatigue syndrome co-occur at rates substantially exceeding population base rates — estimated at 30–60% — supporting the concept of a broader "functional somatic syndrome" spectrum.

Clinical Impact of Comorbidity

Comorbid depression and PTSD are among the strongest predictors of poor functional outcomes and treatment non-response. Untreated anxiety amplifies somatic hypervigilance, perpetuating the cognitive-behavioral cycles that maintain SSD. Dissociative symptoms in FND are associated with greater symptom severity and more frequent functional seizures. These comorbidity patterns underscore that effective treatment rarely involves addressing the somatic symptoms in isolation — comprehensive psychiatric assessment and integrated treatment of co-occurring conditions are essential components of care.

Cognitive behavioral therapy (CBT) is the most extensively studied psychotherapeutic intervention for both SSD and FND, with a strong evidence base from multiple randomized controlled trials and meta-analyses. However, the application of CBT to these conditions requires specific adaptations beyond standard depression- or anxiety-focused protocols.

Theoretical Model

CBT for somatic symptom disorders targets a self-reinforcing cycle: (1) attentional bias toward bodily sensations; (2) catastrophic misinterpretation of these sensations (e.g., "This headache means I have a brain tumor"); (3) behavioral responses that maintain distress, including excessive body checking, reassurance-seeking, avoidance of activity, and repeated medical consultation; (4) emotional distress (anxiety, depression) that further lowers the threshold for somatic symptom perception. The therapeutic aim is to disrupt each node of this cycle through cognitive restructuring, behavioral activation, graduated exposure to feared activities, and interoceptive retraining.

Evidence for CBT in SSD/Somatization

The most robust evidence comes from a Cochrane systematic review (van Dessel et al., 2014) which examined CBT for medically unexplained physical symptoms. Across 21 RCTs, CBT demonstrated small to medium effect sizes for symptom severity (SMD ≈ −0.34, 95% CI −0.53 to −0.16) compared to usual care or waiting list controls. The effect on physical functioning was more modest (SMD ≈ −0.20). These effects were maintained at follow-up periods of 6–12 months. When compared to enhanced medical care, the advantage of CBT diminished somewhat but remained statistically significant.

The landmark PRINCE secondary trial (Chalder et al., 2021, The Lancet) randomized 322 patients with persistent physical symptoms to CBT plus standard medical care versus standard medical care alone. At 52 weeks, the CBT group showed significantly greater improvement on the Patient Health Questionnaire-15 (PHQ-15), with a mean difference of −1.82 points (95% CI −3.18 to −0.45), a modest but clinically meaningful effect. Response rates (≥30% reduction in PHQ-15) were approximately 36% with CBT vs. 24% with standard care.

Evidence for CBT in FND

For functional neurological disorder, the evidence base is growing but less mature. The CODES trial (Goldstein et al., 2020, JAMA Psychiatry) was the largest RCT of CBT for dissociative (psychogenic nonepileptic) seizures. This multisite trial randomized 368 patients with PNES to CBT plus standardized medical care versus standardized medical care alone. The primary outcome — monthly seizure frequency at 12 months — showed no significant difference between groups (adjusted odds ratio 1.02). However, secondary outcomes including seizure bothersomeness, psychological distress, and psychosocial functioning showed significant advantages for CBT. The null primary finding was a sobering result, prompting reconsideration of outcome measures, CBT delivery format, and patient selection. Some post-hoc analyses suggested that patients with lower seizure frequency at baseline and those with comorbid depression showed greater CBT benefit.

For functional motor symptoms, a pilot RCT by Nielsen et al. (2017) demonstrated feasibility and preliminary efficacy of a specialized physiotherapy-augmented intervention informed by cognitive-behavioral principles. Larger trials are underway.

Number Needed to Treat

Based on available data, the NNT for CBT in SSD (compared to standard care for achieving clinically meaningful symptom reduction) is approximately 6–10. For FND/PNES, NNT estimates are less reliable due to the mixed findings from the CODES trial, but secondary outcome data suggest an NNT of approximately 8–12 for meaningful improvement in psychosocial functioning.

Pharmacotherapy for SSD and FND is generally considered adjunctive rather than primary, with the strongest evidence supporting medications targeting comorbid psychiatric conditions rather than somatic symptoms directly.

Antidepressants

SSRIs and SNRIs are the most commonly prescribed medications, with evidence supporting their use primarily through treatment of comorbid depression and anxiety. A meta-analysis by Kleinstäuber et al. (2014) examined antidepressants for somatoform disorders and found moderate effect sizes for symptom reduction (SMD ≈ −0.91 for new-generation antidepressants vs. placebo), though the included studies had significant methodological limitations, including small sample sizes and heterogeneous populations. SNRIs (particularly duloxetine and venlafaxine) may have particular utility given their dual action on serotonergic and noradrenergic pathways, and their established efficacy for chronic pain conditions that frequently co-occur with SSD.

Tricyclic Antidepressants

Older literature supports low-dose tricyclic antidepressants (e.g., amitriptyline 10–75 mg) for functional somatic symptoms, particularly in the context of irritable bowel syndrome and chronic pain. Mechanisms likely include serotonergic and noradrenergic reuptake inhibition, anticholinergic effects on the gut, and modulation of descending pain inhibitory pathways. NNT for TCAs in functional GI disorders is approximately 4–5 based on meta-analytic data.

Anticonvulsants and Other Agents

There is no evidence supporting the use of antiepileptic drugs for PNES, and their use in this context represents a common iatrogenic error. Patients diagnosed with PNES should have anticonvulsants tapered under specialist guidance if they were previously prescribed. Benzodiazepines are generally avoided due to their potential for dependence and paradoxical worsening of dissociative symptoms.

Pharmacotherapy for FND

There are no FDA-approved pharmacotherapies specifically for FND. Treatment is directed at comorbidities. Emerging interest exists in agents targeting specific neurobiological mechanisms — for example, transcranial magnetic stimulation (TMS) targeting the motor cortex or DLPFC — but these remain experimental. A small number of open-label and pilot studies of TMS for functional motor symptoms have shown promising results, but controlled data are insufficient for clinical recommendations.

Given the complexity and multi-system involvement of SSD and FND, multidisciplinary care has emerged as the gold-standard treatment framework. These models integrate neurology, psychiatry, psychology, physiotherapy, occupational therapy, and sometimes speech-language therapy under a coordinated treatment plan.

The Multidisciplinary Model for FND

Specialist FND programs — pioneered at centers including the National Hospital for Neurology and Neurosurgery (Queen Square, London), Massachusetts General Hospital, and the Edinburgh FND service — typically include:

• Neurologist-led diagnosis and psychoeducation: Clear, confident communication of the diagnosis is itself therapeutic. Stone and Edwards (2012) emphasized that diagnosis delivery should be framed positively ("You have functional neurological disorder — a problem with the way the nervous system is functioning, not structural damage") rather than as an exclusion ("We can't find anything wrong").
• Specialized physiotherapy: Physical rehabilitation strategies emphasize movement retraining, distraction techniques, and graded motor imagery. Nielsen et al.'s consensus recommendations (2015) outlined a physiotherapy approach specifically adapted for FND, focusing on normalizing movement patterns by exploiting the known distractibility and variability of functional symptoms.
• Psychological therapy: CBT, acceptance and commitment therapy (ACT), or psychodynamic psychotherapy — selected based on patient preference, comorbidity profile, and symptom presentation.
• Occupational therapy: Functional rehabilitation, activity pacing, and vocational support.
• Psychiatric input: Management of comorbid mood disorders, PTSD, and personality-related difficulties; pharmacotherapy oversight.

Outcome Data for Multidisciplinary Programs

Observational studies from specialist centers report improvement rates of 50–70% in FND symptom severity following intensive multidisciplinary rehabilitation programs, though definitions of "improvement" vary across studies and controlled data are limited. A prospective cohort study from the Edinburgh FND service (Sharpe et al., 2011) demonstrated that a brief, structured neuropsychiatric intervention — involving diagnosis, psychoeducation, and a self-help manual — produced clinically meaningful improvement in approximately 40% of patients at 6-month follow-up.

For inpatient multidisciplinary rehabilitation of severe FND (e.g., functional paraplegia, wheelchair-dependent patients), outcomes data from programs such as the one reported by McCormack et al. (2014) show that approximately 60–70% of patients achieve independent ambulation by discharge, with functional gains partially maintained at 1-year follow-up. However, relapse rates remain high — approximately 30–40% experience symptom recurrence within 1–2 years, underscoring the need for ongoing outpatient support.

Integrated Care for SSD

For somatic symptom disorder, stepped-care models have been proposed, with initial steps involving primary care-based psychoeducation and collaborative care, escalating to specialist CBT and then multidisciplinary programs for refractory cases. The collaborative care model, in which a mental health care manager coordinates between primary care physician, psychiatrist, and patient, has shown significant benefit. A landmark trial by Kroenke et al. (2009) demonstrated that a collaborative care intervention produced significantly greater improvement in somatization severity compared to usual care, with benefits sustained at 12-month follow-up.

Prognostic research in SSD and FND has identified several factors that reliably predict outcome trajectories, which can inform clinical decision-making and patient counseling.

Favorable Prognostic Indicators

• Short symptom duration at presentation: Consistently the strongest predictor of good outcome. Patients presenting within 6–12 months of symptom onset have substantially better prognoses than those with chronic symptoms (>2 years).
• Acute onset: Rapid symptom onset (particularly in FND) is associated with better outcomes than insidious onset.
• Identifiable precipitant: While not required for diagnosis, patients who can identify a clear psychological or physical precipitant tend to respond better to treatment.
• Acceptance of the diagnosis: Patient belief in and acceptance of the FND/SSD diagnosis is a powerful predictor of treatment engagement and outcome.
• Higher baseline functioning: Better premorbid social and occupational functioning predicts recovery.
• Absence of comorbid personality disorder: Personality pathology, particularly borderline personality disorder, is associated with poorer treatment response and higher dropout.

Unfavorable Prognostic Indicators

• Long symptom duration and diagnostic delay: The median diagnostic delay of 5–7 years for FND is itself a prognostic marker — prolonged duration is associated with entrenched illness behavior, iatrogenic harm from unnecessary treatments, and loss of functional capacity.
• Comorbid depression and PTSD: Both independently predict worse functional outcomes.
• Ongoing litigation or disability claims: The role of secondary gain remains controversial, but pending litigation and disability benefit receipt are consistently associated with worse outcomes in outcome studies, though the direction of causality is debated.
• Dissociative seizures (PNES): Among FND subtypes, PNES has a particularly guarded long-term prognosis. The landmark long-term follow-up study by Reuber et al. (2003) found that approximately two-thirds of PNES patients continued to have seizures at 11-year follow-up, and over 50% remained dependent on social welfare.
• Polysymptomatic presentation: Patients with symptoms affecting multiple functional systems (e.g., motor, sensory, cognitive, and visceral) have worse outcomes than those with isolated symptoms.

The manner in which the diagnosis of SSD or FND is communicated has a measurable impact on treatment adherence, patient satisfaction, and clinical outcomes. This aspect of care is often overlooked in medical education but is fundamental to effective management.

Principles of Diagnostic Communication

Research by Stone, Carson, and Hallett (2016) has established several evidence-informed principles:

• Name the diagnosis clearly: Use the term "functional neurological disorder" or "functional [symptom type]." Avoid terms like "psychosomatic," "psychogenic," or "conversion disorder" in patient-facing communication, as these carry strong pejorative connotations and imply the symptoms are "all in your head."
• Explain the mechanism: Analogies such as "a software problem rather than a hardware problem" or "the nervous system is sending the wrong signals" are clinically validated to improve patient understanding and acceptance.
• Demonstrate positive signs: Showing the patient their Hoover's sign or tremor entrainment — evidence that the motor system can function normally — reframes the diagnosis from one of exclusion to one of positive identification and provides tangible evidence that recovery is possible.
• Validate the reality of symptoms: Explicitly state that the symptoms are real, involuntary, and not the patient's fault. This counters the pervasive stigma that patients with FND and SSD encounter.
• Provide written information: Patient-facing resources (e.g., neurosymptoms.org, developed by Jon Stone) have been shown to improve understanding and engagement with treatment.

Studies examining the diagnostic encounter in FND suggest that patients who rate the initial diagnostic communication as clear and empathic show significantly better outcomes at 6 and 12 months compared to those who experience the encounter as dismissive, regardless of the subsequent treatment received.

The field of functional and somatic symptom disorders is undergoing rapid evolution, but important limitations and gaps persist.

Emerging Research Areas

• Predictive processing and computational psychiatry: The application of Bayesian brain models to SSD and FND — conceptualizing symptoms as the product of overweighted top-down predictions about bodily states — is generating testable hypotheses and novel therapeutic targets. Edwards, Adams, Brown, Pareés, and Friston (2012) articulated a comprehensive computational account of FND that has become highly influential.
• Neuroimaging biomarkers: Efforts to identify diagnostic or prognostic neuroimaging markers (e.g., patterns of amygdala-motor cortex connectivity) are underway but not yet clinically applicable. Machine learning approaches to distinguish FND from malingering or neurological disease based on brain imaging patterns are in early development.
• Transcranial magnetic stimulation (TMS): Several small studies and case series suggest that TMS targeting the motor cortex or DLPFC may benefit some FND patients, possibly by modulating the disrupted prefrontal-motor connectivity described above. Controlled trials are needed.
• Psychedelic-assisted therapy: Very preliminary interest exists in psilocybin-assisted therapy for treatment-resistant somatic symptom disorders, based on the hypothesis that psychedelics may "relax" rigid predictive priors. This remains speculative.
• Genetics and epigenetics: GWAS studies have not yet been conducted specifically for SSD or FND. Epigenetic studies of trauma-exposed cohorts offer indirect evidence, but direct epigenetic studies in diagnosed FND/SSD populations are needed.

Major Limitations of Current Evidence

• Trial quality: Most RCTs in this field are small, underpowered, and heterogeneous in outcome measures. The CODES trial was a notable exception, and its null primary finding highlighted the challenges of conducting well-powered trials in this population.
• Outcome measure inconsistency: There is no consensus on a primary outcome measure for FND or SSD trials. Symptom frequency, severity, functional impairment, quality of life, and healthcare utilization are all used, making cross-study comparison difficult.
• Diagnostic heterogeneity: SSD and FND encompass extraordinarily diverse symptom presentations. Grouping functional seizures, functional weakness, functional cognitive symptoms, and complex regional-pain-like presentations under a single diagnostic umbrella may obscure treatment-specific effects.
• Limited long-term data: Most treatment studies report outcomes at 6–12 months. Long-term follow-up data (3–5+ years) are scarce, despite evidence that relapse is common.
• Underrepresentation of diverse populations: Most research cohorts are predominantly white, female, and from high-income countries. The generalizability of findings to diverse ethnic, cultural, and socioeconomic populations is unknown.

Somatic symptom disorder and functional neurological disorder are prevalent, disabling, and neurobiologically grounded conditions that demand clinical expertise spanning neurology, psychiatry, and psychology. Key clinical implications include:

• Diagnosis should be made early and positively, based on recognized clinical signs and criteria — not merely as an exclusion of organic disease. Diagnostic delay is a modifiable risk factor for chronicity.
• CBT is the best-supported psychotherapy, though effect sizes are modest (NNT ≈ 6–10 for SSD), and the CODES trial highlighted that seizure frequency in PNES may not respond as expected. Treatment selection should be individualized based on symptom type, comorbidity, and patient preference.
• Pharmacotherapy plays a supporting role, primarily targeting comorbid depression, anxiety, and chronic pain. There is no specific pharmacological treatment for FND itself.
• Multidisciplinary care represents the gold standard for moderate-to-severe presentations, integrating neurology, physiotherapy, psychology, and psychiatry. Specialist FND services achieve improvement rates of 50–70%, but relapse rates of 30–40% indicate the need for sustained follow-up.
• Therapeutic communication is itself an intervention. The quality of the diagnostic encounter predicts downstream outcomes and should be treated as a core clinical skill.
• Comorbidities must be assessed and treated aggressively, as untreated depression, PTSD, and dissociative symptoms are among the strongest predictors of poor outcome.

The growing integration of neuroimaging, computational models, and precision medicine approaches holds promise for transforming the diagnosis and treatment of these conditions. However, the most impactful clinical intervention available today remains a knowledgeable clinician who takes the patient seriously, communicates the diagnosis with clarity and empathy, and coordinates evidence-based multidisciplinary care.